According to Biolidics, commercial production for the ClearEpi NAB Test is expected to commence in the current financial year ending Dec 31.
On Dec 8, Biolidics announced it has entered into a definitive agreement with its contract manufacturer for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (ClearEpi NAB Test) which can be used to detect a person's protective immunity against Covid-19 infections.
The company has also obtained the relevant product liability insurance for the ClearEpi NAB Test.
